CHURCH OF PEPTIDES / THE 60-SECOND GUIDE

Liraglutide

Approved human use · product-specific labels.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Liraglutide is a GLP-1 receptor agonist used in separately labeled medicines for type 2 diabetes and chronic weight management. Its glucose and appetite effects come with product-specific eligibility, warnings, and limitations. [1]

02 Potential benefits

Approved products support glycemic control or chronic weight management under separate labels. Its engineered structure extends GLP-1 receptor activity. [1]

03 Evidence & its limits

Evidence for a diabetes product does not automatically establish every weight-management claim. Liraglutide products carry significant warnings, including thyroid C-cell tumor concerns; gastrointestinal effects and pancreatitis, gallbladder, and kidney-related precautions also require attention to the applicable label. [1]

04 Risks & unknowns

Gastrointestinal effects are common. Contraindications, interactions, and boxed-warning context must follow the exact product. [1]

05 Status & scope

Approved human use · product-specific labels. Read the full record for product, formulation and indication-specific status; a biological role or measured response is not a treatment approval. [1]

06 November 2026 safety update

FDA requires a warning about a potential increased risk of NAION, a rare optic-nerve condition that can cause permanent vision loss. Seek prompt medical attention for sudden painless vision loss or other visual changes. Individual labels may still be undergoing revision. [4]

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] FDA Drugs@FDA database
[3] FDA clinical review: liraglutide approval history
[4] FDA / GLP-1 eye-safety notice / November 9, 2026

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.